Moreover, PI3K, AKT, or mTOR inhibitors alone are not very efficient in CRC treatment, because drug resistance appears to be driven by Wnt/β-catenin or by MAPK signaling pathways’ components. The gene discussed is AKT1; the disease is colorectal carcinoma.